Cognitive behavioral therapy for insomnia (CBTI) targets changing dysfunctional sleep-related beliefs. The impact of these changes on daytime functioning in older adults is unknown. We examined whether changes in sleep-related beliefs from pre- to post-CBTI predicted changes in sleep and other outcomes in older adults. Data included 144 older veterans with insomnia from a randomized controlled trial testing CBTI. Sleep-related beliefs were assessed with the Dysfunctional Beliefs and Attitudes about Sleep-16 (DBAS-16, subscales Consequences, Worry/Helplessness, Sleep Expectations, Medication). Outcomes included sleep diary variables, actigraphy-measured sleep efficiency, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), Flinders Fatigue Scale (FFS), Patient Health Questionnaire-9, and health-related quality of life. Analyses compared slope of change in DBAS subscales from baseline to posttreatment between CBTI and control, and assessed the relationship between DBAS change and the slope of change in outcomes from baseline to 6 months. Compared to controls, the CBTI group demonstrated stronger associations between improvement in DBAS-Consequences and subsequent improvement in PSQI, ISI, ESS, and FFS. The CBTI group also demonstrated stronger associations between improvement in DBAS-Worry/Helplessness and subsequent improvements in PSQI, ISI, and FFS; improvements in DBAS-Medication and PSQI; and improvements in DBAS-Sleep Expectations and wake after sleep onset (sleep diary) and FFS (all p < .05). Significant reduction in dysfunctional sleep-related beliefs following CBTI in older adults predicted improvement in several outcomes of sleep and daytime functioning. This suggests the importance of addressing sleep-related beliefs for sustained improvement with CBTI in older veterans. ClinicalTrials.gov Identifier NCT00781963. ClinicalTrials.gov Identifier NCT00781963.Humans can grasp the "average" feature of a visual ensemble quickly and effortlessly. However, it is largely unknown what is the exact form of the summary statistic humans perceive and it is even less known whether this form can be changed by feedback. Here we borrow the concept of loss function to characterize how the summary perception is related to the distribution of feature values in the ensemble, assuming that the summary statistic minimizes a virtual expected loss associated with its deviation from individual feature values. In two experiments, we investigated a random-dot motion estimation task to infer the virtual loss function implicit in ensemble perception and see whether it can be changed by feedback. https://www.selleckchem.com/products/Trichostatin-A.html On each trial, participants reported the average moving direction of an ensemble of moving dots whose distribution of moving directions was skewed. In Experiment 1, where no feedback was available, participants' estimates fell between the mean and the mode of the distribution and were closer to the mean. In particular, the deviation from the mean and toward the mode increased almost linearly with the mode-to-mean distance. The pattern was best modeled by an inverse Gaussian loss function, which punishes large errors less heavily than the quadratic loss function does. In Experiment 2, we tested whether this virtual loss function can be altered by feedback. Two groups of participants either received the mode or the mean as the correct answer. After extensive training up to five days, both groups' estimates moved slightly towards the mode. That is, feedback had no specific influence on participants' virtual loss function. To conclude, the virtual loss function in the summary perception of motion is close to inverse Gaussian, and it can hardly be changed by feedback.The vision sciences literature contains a large diversity of experimental and theoretical approaches to the study of visual attention. We argue that this diversity arises, at least in part, from the field's inability to unify differing theoretical perspectives. In particular, the field has been hindered by a lack of a principled formal framework for simultaneously thinking about both optimal attentional processing and capacity-limited attentional processing, where capacity is limited in a general, task-independent manner. Here, we supply such a framework based on rate-distortion theory (RDT) and optimal lossy compression. Our approach defines Bayes-optimal performance when an upper limit on information processing rate is imposed. In this article, we compare Bayesian and RDT accounts in both uncued and cued visual search tasks. We start by highlighting a typical shortcoming of unlimited-capacity Bayesian models that is not shared by RDT models, namely, that they often overestimate task performance when information-processing demands are increased. Next, we reexamine data from two cued-search experiments that have previously been modeled as the result of unlimited-capacity Bayesian inference and demonstrate that they can just as easily be explained as the result of optimal lossy compression. To model cued visual search, we introduce the concept of a "conditional communication channel." This simple extension generalizes the lossy-compression framework such that it can, in principle, predict optimal attentional-shift behavior in any kind of perceptual task, even when inputs to the model are raw sensory data such as image pixels. To demonstrate this idea's viability, we compare our idealized model of cued search, which operates on a simplified abstraction of the stimulus, to a deep neural network version that performs approximately optimal lossy compression on the real (pixel-level) experimental stimuli. PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum. The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines. This was a multicenter, open-label, repeat-dose, 1-year phase II safety study. Adults with moderate to severe glabellar lines at maximum frown, as assessed by the investigator on the validated 4-point photonumeric Glabellar Line Scale (0 = no lines, 1 = mild, 2 = moderate, 3 = severe), were enrolled. On day 0, patients received an initial treatment of 20 U prabotulinumtoxinA (4 U/0.1 mL freeze-dried formulation injected into 5 target glabellar sites). On and after day 90, patients received a repeat treatment (RT) if their Glabellar Line Scale score was ≥2 at maximum frown by investigator assessment. Safety was evaluated throughout the study. The 352 study patients received a median total dose of 60 U, that is, 3 treatments per year. Fifty-one patients (14.5%) experienced adverse events (AEs) assessed as possibly study drug related; 11.